Physician profile
Daniel Ely
NPI 1194744516
$1,214.82
in general payments reported to CMS, 2019-2025
18 companies · $31.06 in 2025
The $31.06 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $145 · 2021: $194 · 2022: $99.99 · 2023: $42.19 · 2024: $191 · 2025: $31.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $428.91 | 2019-2025 | Biktarvy |
| Janssen Products, Lp | $309.98 | 2019-2022 | |
| Janssen Biotech, INC. | $98.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.93 | 2019-2021 | |
| Viiv Healthcare Company | $47.52 | 2019-2020 | |
| Amgen INC. | $39.36 | 2019-2020 | |
| Pfizer INC. | $36.48 | 2019-2020 | |
| Theratechnologies INC. | $28.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $25.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.50 | 2019 | |
| La Jolla Pharmaceutical Company | $23.43 | 2024 | Xerava |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Astellas Pharma US INC | $16.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.66 | 2024 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.39 | 2019 | |
| Glaxosmithkline, LLC. | $11.37 | 2019 | |
| Novo Nordisk INC | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.